JP2016512511A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512511A5 JP2016512511A5 JP2016500985A JP2016500985A JP2016512511A5 JP 2016512511 A5 JP2016512511 A5 JP 2016512511A5 JP 2016500985 A JP2016500985 A JP 2016500985A JP 2016500985 A JP2016500985 A JP 2016500985A JP 2016512511 A5 JP2016512511 A5 JP 2016512511A5
- Authority
- JP
- Japan
- Prior art keywords
- butoxy
- tert
- acetic acid
- methylpyrazolo
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- -1 benzoimidazolyl Chemical group 0.000 claims 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000003302 alkenyloxy group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 125000005336 allyloxy group Chemical group 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- LZOZJWGPUDSKFN-UHFFFAOYSA-N 8-fluoro-5-methyl-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=C1C(F)=CC=C2C LZOZJWGPUDSKFN-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 230000034303 cell budding Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- CWOLTMOLAIYUFS-XIFFEERXSA-N (2S)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2H-chromen-6-yl)-5-methyl-2-(6-phenyl-1H-benzimidazol-2-yl)pyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound Cc1nc2cc(nn2c(-c2cc(F)c3OCCCc3c2C)c1[C@H](OC(C)(C)C)C(O)=O)-c1nc2cc(ccc2[nH]1)-c1ccccc1 CWOLTMOLAIYUFS-XIFFEERXSA-N 0.000 claims 1
- JARWJCRLYLIATB-SANMLTNESA-N (2s)-2-[2-(1-benzylpyrazol-4-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C3=CN(CC=4C=CC=CC=4)N=C3)=NN2C=1N1CCC(C)(C)CC1 JARWJCRLYLIATB-SANMLTNESA-N 0.000 claims 1
- OSLZWNQMOQESGQ-VWLOTQADSA-N (2s)-2-[2-(3-benzyl-2-oxoimidazolidin-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C(N(CC=4C=CC=CC=4)CC3)=O)=NN2C=1N1CCC(C)(C)CC1 OSLZWNQMOQESGQ-VWLOTQADSA-N 0.000 claims 1
- RMXYVRPUEQROKQ-SANMLTNESA-N (2s)-2-[2-(3-benzylpyrazol-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3N=C(CC=4C=CC=CC=4)C=C3)=NN2C=1N1CCC(C)(C)CC1 RMXYVRPUEQROKQ-SANMLTNESA-N 0.000 claims 1
- RXCWGEDNAQJWCW-QBGQUKIHSA-N (2s)-2-[2-(4-benzyl-2-oxo-1,3-oxazolidin-3-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C(OCC3CC=3C=CC=CC=3)=O)=NN2C=1N1CCC(C)(C)CC1 RXCWGEDNAQJWCW-QBGQUKIHSA-N 0.000 claims 1
- UUFIOPPDYIQUQS-VWLOTQADSA-N (2s)-2-[2-(4-benzyl-3-chloropyrazol-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3N=C(Cl)C(CC=4C=CC=CC=4)=C3)=NN2C=1N1CCC(C)(C)CC1 UUFIOPPDYIQUQS-VWLOTQADSA-N 0.000 claims 1
- APJCPLYCGMOTQA-SANMLTNESA-N (2s)-2-[2-(4-benzylimidazol-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C=C(CC=4C=CC=CC=4)N=C3)=NN2C=1N1CCC(C)(C)CC1 APJCPLYCGMOTQA-SANMLTNESA-N 0.000 claims 1
- IYLUTKNUURMKLM-SANMLTNESA-N (2s)-2-[2-(4-benzylpyrazol-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3N=CC(CC=4C=CC=CC=4)=C3)=NN2C=1N1CCC(C)(C)CC1 IYLUTKNUURMKLM-SANMLTNESA-N 0.000 claims 1
- UEMTXTCLWRVXMH-QBGQUKIHSA-N (2s)-2-[2-(5-benzyl-2-oxo-1,3-oxazolidin-3-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C(OC(CC=4C=CC=CC=4)C3)=O)=NN2C=1N1CCC(C)(C)CC1 UEMTXTCLWRVXMH-QBGQUKIHSA-N 0.000 claims 1
- AMNYYVYPODVSTK-SANMLTNESA-N (2s)-2-[2-(5-benzylpyrazol-1-yl)-7-(4,4-dimethylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C(=CC=N3)CC=3C=CC=CC=3)=NN2C=1N1CCC(C)(C)CC1 AMNYYVYPODVSTK-SANMLTNESA-N 0.000 claims 1
- MHIXTSDZCWLPNI-VWLOTQADSA-N (2s)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methyl-7-(4-methyl-3,6-dihydro-2h-pyridin-1-yl)pyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1CC(C)=CCN1C1=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN12 MHIXTSDZCWLPNI-VWLOTQADSA-N 0.000 claims 1
- ICNMTMFUUIWPNH-PMERELPUSA-N (2s)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methyl-7-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)pyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N(CC=1)CCC=1C1=CC=CC=C1 ICNMTMFUUIWPNH-PMERELPUSA-N 0.000 claims 1
- WGFWHGVZSUYWMN-DEOSSOPVSA-N (2s)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-7-(4-hydroxy-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N1CCC(C)(O)CC1 WGFWHGVZSUYWMN-DEOSSOPVSA-N 0.000 claims 1
- AMCBTFLGLPPAOR-VWLOTQADSA-N (2s)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-7-(4-methoxy-4-methylpiperidin-1-yl)-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1CC(OC)(C)CCN1C1=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN12 AMCBTFLGLPPAOR-VWLOTQADSA-N 0.000 claims 1
- KFXSYVHURPBUJH-VWLOTQADSA-N (2s)-2-[2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-7-[4-(hydroxymethyl)-4-methylpiperidin-1-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N1CCC(C)(CO)CC1 KFXSYVHURPBUJH-VWLOTQADSA-N 0.000 claims 1
- XFFFHJRJTNOYIU-MHZLTWQESA-N (2s)-2-[7-(4,4-dimethylcyclohexyl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1C1CCC(C)(C)CC1 XFFFHJRJTNOYIU-MHZLTWQESA-N 0.000 claims 1
- WCICUWAODBICEH-VWLOTQADSA-N (2s)-2-[7-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N1CCC(C)(C)CC1 WCICUWAODBICEH-VWLOTQADSA-N 0.000 claims 1
- SFLJSPLNMRWBAV-MHZLTWQESA-N (2s)-2-[7-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CC=3)=NN2C=1N1CCC(C)(C)CC1 SFLJSPLNMRWBAV-MHZLTWQESA-N 0.000 claims 1
- KAWLRRIDNLNTEZ-IHZSNKTASA-N (2s)-2-[7-(4,4-dimethylpiperidin-1-yl)-2-[5-[1-(4-fluorophenyl)ethyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C=1C=C(F)C=CC=1C(C)C(S1)=CN=C1C(=NN12)C=C1N=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C2N1CCC(C)(C)CC1 KAWLRRIDNLNTEZ-IHZSNKTASA-N 0.000 claims 1
- JOIROVAPLYJWCW-SANMLTNESA-N (2s)-2-[7-(4,4-dimethylpiperidin-1-yl)-2-[5-[2-(4-fluorophenyl)ethyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CCC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N1CCC(C)(C)CC1 JOIROVAPLYJWCW-SANMLTNESA-N 0.000 claims 1
- QGIUCHRNNBHRCK-QBGQUKIHSA-N (2s)-2-[7-(4,4-dimethylpiperidin-1-yl)-5-methyl-2-(2-oxo-3-phenoxypyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(N3C(C(OC=4C=CC=CC=4)CC3)=O)=NN2C=1N1CCC(C)(C)CC1 QGIUCHRNNBHRCK-QBGQUKIHSA-N 0.000 claims 1
- VOTWBINOKCQRML-MHZLTWQESA-N (2s)-2-[7-(4-cyclopropyl-4-methylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN2C=1N(CC1)CCC1(C)C1CC1 VOTWBINOKCQRML-MHZLTWQESA-N 0.000 claims 1
- MDIYXGKYEMEDME-SANMLTNESA-N (2s)-2-[7-(4-ethyl-4-methylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1CC(CC)(C)CCN1C1=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=NN12 MDIYXGKYEMEDME-SANMLTNESA-N 0.000 claims 1
- YAVQIOMBGSKMCJ-LJAQVGFWSA-N (2s)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[3-[(4-fluorophenyl)methyl]-1,2,4-oxadiazol-5-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound N=1N2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC=1C(ON=1)=NC=1CC1=CC=C(F)C=C1 YAVQIOMBGSKMCJ-LJAQVGFWSA-N 0.000 claims 1
- HUECDZXIUWSMDZ-LJAQVGFWSA-N (2s)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-(3-fluorophenyl)-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound N=1N2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC=1C(S1)=NC=C1C1=CC=CC(F)=C1 HUECDZXIUWSMDZ-LJAQVGFWSA-N 0.000 claims 1
- FWHOVQXUKGGDIE-LJAQVGFWSA-N (2s)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound N=1N2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC=1C(S1)=NC=C1C1=CC=C(F)C=C1 FWHOVQXUKGGDIE-LJAQVGFWSA-N 0.000 claims 1
- RNBBOMASJBJJIZ-PMERELPUSA-N (2s)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound N=1N2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC=1C(O1)=NC=C1CC1=CC=C(F)C=C1 RNBBOMASJBJJIZ-PMERELPUSA-N 0.000 claims 1
- ZKSHDNQVKPHIQJ-PMERELPUSA-N (2s)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2h-chromen-6-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-5-methylpyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound N=1N2C(C=3C(=C4CCCOC4=C(F)C=3)C)=C([C@H](OC(C)(C)C)C(O)=O)C(C)=NC2=CC=1C(S1)=NC=C1CC1=CC=C(F)C=C1 ZKSHDNQVKPHIQJ-PMERELPUSA-N 0.000 claims 1
- RRZVGDGTWNQAPW-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile Chemical compound C1=NN(C)C=C1CCN1C(C=2C=CC(=CC=2)C#N)=C(C2=CN(C)N=C2)N=C1 RRZVGDGTWNQAPW-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779858P | 2013-03-13 | 2013-03-13 | |
| US61/779,858 | 2013-03-13 | ||
| PCT/US2014/022501 WO2014164467A1 (en) | 2013-03-13 | 2014-03-10 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512511A JP2016512511A (ja) | 2016-04-28 |
| JP2016512511A5 true JP2016512511A5 (enExample) | 2017-04-13 |
Family
ID=50478938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500985A Ceased JP2016512511A (ja) | 2013-03-13 | 2014-03-10 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9580431B2 (enExample) |
| EP (1) | EP2970298A1 (enExample) |
| JP (1) | JP2016512511A (enExample) |
| CN (1) | CN105189511B (enExample) |
| WO (1) | WO2014164467A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2015174511A1 (ja) | 2014-05-16 | 2015-11-19 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| SG11201709634QA (en) | 2015-05-29 | 2017-12-28 | Shionogi & Co | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| US20180170903A1 (en) | 2015-07-06 | 2018-06-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| EP3319957A1 (en) | 2015-07-08 | 2018-05-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| AU2016290986A1 (en) | 2015-07-09 | 2018-01-18 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| RU2018103031A (ru) | 2015-07-09 | 2019-08-09 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | Производные пиридин-3-ил уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |
| KR20180035910A (ko) | 2015-08-07 | 2018-04-06 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체 |
| CN108026113A (zh) | 2015-08-10 | 2018-05-11 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物 |
| TWI657086B (zh) | 2015-08-11 | 2019-04-21 | 英商Viiv醫療保健英國(No.5)有限公司 | 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物 |
| CA2995087A1 (en) | 2015-08-12 | 2017-02-16 | John F. Kadow | 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| CN108137553A (zh) | 2015-08-12 | 2018-06-08 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的5-(n-[6,5]-稠合双环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物 |
| TW201718537A (zh) * | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| US10106504B2 (en) | 2015-08-20 | 2018-10-23 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US10407410B2 (en) | 2016-05-11 | 2019-09-10 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2017195112A1 (en) | 2016-05-11 | 2017-11-16 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2019515939A (ja) | 2016-05-11 | 2019-06-13 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| US20200055839A1 (en) | 2017-01-03 | 2020-02-20 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20200016136A1 (en) | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US10234220B2 (en) * | 2017-04-14 | 2019-03-19 | Kent J. Myers | Detachable box magazine with follower retraction member |
| SG11202006453SA (en) * | 2018-01-17 | 2020-08-28 | Glaxosmithkline Ip Dev Ltd | Pi4kiiibeta inhibitors |
| WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020081856A1 (en) * | 2018-10-18 | 2020-04-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibitors of hiv-1 nef for the treatment of hiv disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401436D0 (en) | 1994-01-26 | 1994-03-23 | Wellcome Found | Therapeutic heterocyclic compounds |
| HUP0102404A2 (hu) | 1998-02-04 | 2001-11-28 | Banyu Pharmaceutical Co., Ltd. | N-acilezett gyűrűs aminszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények |
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| RU2450004C2 (ru) | 2006-08-04 | 2012-05-10 | Мерц Фарма Гмбх Унд Ко. Кгаа | Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства |
| EP2173745A2 (en) | 2007-03-23 | 2010-04-14 | Array Biopharma, Inc. | 2-aminopyridine analogs as glucokinase activators |
| JP5269086B2 (ja) | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
| US7956068B2 (en) | 2007-11-15 | 2011-06-07 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| JP5269087B2 (ja) | 2007-11-16 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
| US8353602B2 (en) | 2007-11-23 | 2013-01-15 | Koninklijke Philips Electronics N.V. | Compartment |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| SG181423A1 (en) * | 2009-12-23 | 2012-07-30 | Univ Leuven Kath | Novel antiviral compounds |
| SG186821A1 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| AP2013006706A0 (en) | 2010-07-02 | 2013-02-28 | Gilead Sciences Inc | Napht-2-ylacetic acid derivatives to treat AIDS |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| NZ610315A (en) | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| CA2817896A1 (en) | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) * | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2014
- 2014-03-10 EP EP14717006.2A patent/EP2970298A1/en active Pending
- 2014-03-10 WO PCT/US2014/022501 patent/WO2014164467A1/en not_active Ceased
- 2014-03-10 JP JP2016500985A patent/JP2016512511A/ja not_active Ceased
- 2014-03-10 US US14/772,146 patent/US9580431B2/en not_active Expired - Fee Related
- 2014-03-10 CN CN201480026834.8A patent/CN105189511B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512511A5 (enExample) | ||
| JP2016512558A5 (enExample) | ||
| JP2016512507A5 (enExample) | ||
| JP2012502099A5 (enExample) | ||
| JP2011500806A5 (enExample) | ||
| US20090105263A1 (en) | Heterobicyclic compounds as glucokinase activators | |
| JP2008523041A5 (enExample) | ||
| JP2007519649A5 (enExample) | ||
| JP2015524841A5 (enExample) | ||
| JP2008513514A5 (enExample) | ||
| NZ601656A (en) | Pyridyloxyindoles inhibitors of VEGF-R2 and use thereof for treatment of disease | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| HRP20200575T1 (hr) | Spojevi karbamata i postupci pripremanja i korištenja istih | |
| NZ592792A (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| JP2011513475A5 (enExample) | ||
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| RU2014107463A (ru) | Селективные ингибиторы протеинкиназ | |
| JP2017529389A5 (enExample) | ||
| JP2016500068A5 (enExample) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2008516936A (ja) | ２型糖尿病および肥満の処置において有用であるフェノキシベンズアミド化合物 | |
| JP2016516692A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| JP2013535414A5 (enExample) |